Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. (NEUP): 6 pipeline candidates · ~50 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
49.8 months
D/E 0.18 · 1% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for Neuphoria Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$22.9M
Cash
$19.4M
Quarterly Burn
$1.2M
Runway
49.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$5.9M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 875,328 | $3.6M |
| advisorshares investments llc | 155,367 | $632K |
| balyasny asset management l.p. | 142,183 | $579K |
| vanguard capital management llc | 98,516 | $401K |
| geode capital management, llc | 52,007 | $212K |
| vanguard fiduciary trust co | 33,589 | $137K |
| adar1 capital management, llc | 30,000 | $122K |
| citadel advisors llc | 19,331 | $79K |
| boothbay fund management, llc | 14,000 | $57K |
| commonwealth equity services, llc | 11,222 | $46K |
Showing top 10 of 15 institutional holders of Neuphoria Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Neuphoria Therapeutics Inc.'s pipeline?
Neuphoria Therapeutics Inc. (NEUP) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Neuphoria Therapeutics Inc.'s lead drug candidate?
Neuphoria Therapeutics Inc.'s most advanced tracked candidate is bnc210 (Phase 3) for Social Anxiety Disorder (SAD).
What is Neuphoria Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Neuphoria Therapeutics Inc. has approximately 49.8 months of cash runway.
What is Neuphoria Therapeutics Inc.'s market capitalization?
Neuphoria Therapeutics Inc.'s market capitalization is approximately $22.9M.
Who is the CEO of Neuphoria Therapeutics Inc.?
Dr. Spyridon Papapetropoulos M.D., Ph.D. is the chief executive officer of Neuphoria Therapeutics Inc. (NEUP).
Get the full picture on Neuphoria Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.